GlaxoSmithKline plc (GSKN) — Capital Reinvestment Ratio
GlaxoSmithKline plc (GSKN) has a Capital Reinvestment Ratio of 0.40x as of September 2025, meaning it reinvests 0% of its operating cash flow (MX$2.22 Billion) in capital expenditures (MX$879.00 Million). Check GSKN tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
GlaxoSmithKline plc Capital Reinvestment Ratio (2013–2024)
This chart tracks GlaxoSmithKline plc's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see GlaxoSmithKline plc (GSKN) cash flow conversion.
Annual Capital Reinvestment Ratio for GlaxoSmithKline plc (2013–2024)
Year-by-year Capital Reinvestment Ratio for GlaxoSmithKline plc from 2013 to 2024. See GSKN FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (MXN) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.45x | MX$6.55 Billion | MX$2.98 Billion | ▲ +7.8% |
| 2023 | 0.42x | MX$5.48 Billion | MX$2.31 Billion | ▲ +173.4% |
| 2022 | 0.15x | MX$7.40 Billion | MX$1.14 Billion | ▲ +29.2% |
| 2021 | 0.12x | MX$7.95 Billion | MX$950.00 Million | ▲ +2.0% |
| 2020 | 0.12x | MX$8.44 Billion | MX$989.00 Million | ▼ -25.7% |
| 2019 | 0.16x | MX$8.02 Billion | MX$1.26 Billion | ▼ -1.2% |
| 2018 | 0.16x | MX$8.42 Billion | MX$1.34 Billion | ▼ -28.5% |
| 2017 | 0.22x | MX$6.92 Billion | MX$1.54 Billion | ▼ -38.3% |
| 2016 | 0.36x | MX$6.50 Billion | MX$2.35 Billion | ▼ -32.6% |
| 2015 | 0.54x | MX$2.57 Billion | MX$1.38 Billion | ▲ +134.0% |
| 2014 | 0.23x | MX$5.18 Billion | MX$1.19 Billion | ▲ +39.5% |
| 2013 | 0.16x | MX$7.22 Billion | MX$1.19 Billion | — |